CALGB C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Print this page

CALGB C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy (FOLFOX) or standard chemotherapy with 3 years of celecoxib 400 mg daily.

Protocol Number071008
Principal InvestigatorRebecca Moss
PhasePhase III
ScopeNational
Applicable Disease SitesColon
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedFOLFOX
CELECOXIB/PLACEBO
Participating InstitutionsRobert Wood Johnson University Hospital at Hamilton
Rutgers Cancer Institute of New Jersey
Robert Wood Johnson University Hospital Somerset

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.